Page last updated: 2024-10-30

khellin and Chronic Illness

khellin has been researched along with Chronic Illness in 21 studies

Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.

Research Excerpts

ExcerptRelevanceReference
" Severe adverse effects were not observed."2.79Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids. ( Chang, H; Ha, SW; Kim, IH; Song, C; Wu, HG, 2014)
"Keloids are considered as benign fibroproliferative skin tumors growing beyond the site of the original dermal injury."2.61Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies. ( Bayat, A; Khumalo, N; Tan, S, 2019)
"Autophagy induction by rapamycin treatment in keloid fibroblasts effectively suppressed expression levels of Notch1 and NLRP3 inflammasome proteins."1.56Contribution of Autophagy-Notch1-Mediated NLRP3 Inflammasome Activation to Chronic Inflammation and Fibrosis in Keloid Fibroblasts. ( Kang, H; Kim, JE; Kim, SK; Lee, DG; Lee, KJ; Lee, S; Lee, YJ; Park, H; Park, SH, 2020)
"Keloid is a clinically intractable fibro-proliferative disease that spreads beyond the original scar or lesion."1.39Keloid formation on the great toe after chronic paronychia secondary to ingrown nail. ( Burm, JS; Lee, KW; Yang, WY, 2013)
"In the event that a keloid is presented in isolation, chronic osteomyelitis should be considered as a differential diagnosis, and a high index of suspicion is required in order to establish the diagnosis."1.37Chronic osteomyelitis in the lower extremity predisposing to the unusual formation of keloids. ( Olabanji, JK; Oladele, AO; Orimolade, EA; Yusuf, MB, 2011)
"Verneuil's disease (hidradenitis suppurativa) is a chronic inflammatory, suppurating and fistulizing disease of apocrine sweat gland-bearing skin."1.31[Surgical treatment of Verneuil's disease (hidradenitis suppurativa): 15 cases]. ( Destrumelle, N; Dupond, AS; Humbert, P; Lamfichekh, N; Mantion, G; Runser, C, 2001)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-199010 (47.62)18.7374
1990's1 (4.76)18.2507
2000's3 (14.29)29.6817
2010's6 (28.57)24.3611
2020's1 (4.76)2.80

Authors

AuthorsStudies
SILBER, EN1
SNIDER, GL1
GOLDBERG, H1
KATZ, LN2
RADNER, DB1
ROSENMAN, RH1
FISHMAN, AP1
KAPLAN, SR1
LEVIN, HG1
Virchow, C1
Debelic, M1
Klein, HG1
Tan, S1
Khumalo, N1
Bayat, A1
Lee, S1
Kim, SK1
Park, H1
Lee, YJ1
Park, SH1
Lee, KJ1
Lee, DG1
Kang, H1
Kim, JE1
Lee, KW1
Burm, JS1
Yang, WY1
Kanumuri, VV1
Raikundalia, MD1
Khan, MN1
Husain, Q1
Vasquez, A1
Eloy, JA1
Song, C1
Wu, HG1
Chang, H1
Kim, IH1
Ha, SW1
Thiboutot, D1
Gollnick, H1
Bettoli, V1
Dréno, B1
Kang, S1
Leyden, JJ1
Shalita, AR1
Lozada, VT1
Berson, D1
Finlay, A1
Goh, CL1
Herane, MI1
Kaminsky, A1
Kubba, R1
Layton, A1
Miyachi, Y1
Perez, M1
Martin, JP1
Ramos-E-Silva, M1
See, JA1
Shear, N1
Wolf, J1
Davison, SP1
Sobanko, JF1
Clemens, MW1
Orimolade, EA1
Olabanji, JK1
Oladele, AO1
Yusuf, MB1
Lebedeva, LV1
Nikolaeva, NV1
Katz, BE1
Kim, WJ1
Lamfichekh, N1
Dupond, AS1
Destrumelle, N1
Runser, C1
Humbert, P1
Mantion, G1
Jaramillo, D1
Cortés, A1
Restrepo, A1
Builes, M1
Robledo, M1
Zabolotskiĭ, AT1
Sizov, VM1
Lositskaia, VM1
Achten, G1
Bourlond, A1
Haven, E1
Lapière, CM1
Piérard, J1
Reynaers, H1
Sharapova, GIa1
Khamaganova, AV1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173]Phase 460 participants (Actual)Interventional2016-04-30Completed
Autologous Fat Cells Transfer for the Treatment of Atrophic Post Acne Scars: Clinical Trail[NCT05028283]69 participants (Actual)Interventional2021-08-19Completed
A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne[NCT03450369]Phase 110 participants (Actual)Interventional2018-01-24Completed
Serum apelin12 in Acne Vulgaris[NCT03480503]90 participants (Anticipated)Observational2018-05-31Not yet recruiting
Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial.[NCT00849004]75 participants (Anticipated)Interventional2009-03-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Successful Engraftment of Probiotic Following a Single Application.

Engraftment is defined as the percentage of bacteria recovered from hair follicles that are health-associated (NB01) as measured with proprietary quantitative polymerase chain assays. Successful follicular engraftment, defined as both deoR/PanBac >40% and Cas5/PanBac >40% in the Day 2 (24H) ) Biore Strip samples. Cas5/PanBac and deoR/PanBac are the percentages of bacteria in a sample containing the CRISPR associated protein Cas5 and a repressor of porphyrin production deoR, respectively. Pan-Bacterial (PanBac) is a loci found in nearly all bacteria found on the face and thus serves as the denominator to calculate the percentage of bacteria with any loci. (NCT03450369)
Timeframe: 2 Months

InterventionParticipants (Count of Participants)
Low Dose2
High Dose1

Dose Schedule Determination Based on Time to Peak deoR and Cas5

To determine longevity of the live biotherapeutic after a single application, swab samples were collected at Baseline, 6, 24 and 48 hours after application, and genotyped as above. For each participant the absolute change, from Baseline, in the percentage of the two loci present in the live biotherapeutic (deoR and Cas5) were calculated. A significant positive change is indicative of the continued presence of the live biotherapeutic. (NCT03450369)
Timeframe: From Baseline to 48 hours after application

,
Intervention% of total bacteria w/ genotype (Mean)
Genotype 1 (deoR), 6 hoursGenotype 1 (deoR), 24 hoursGenotype 1 (deoR), 48 hoursGenotype 2 (Cas 5), 6 hoursGenotype 2 (Cas 5), 24 hoursGenotype 2 (Cas 5), 48 hours
High Dose51.25.22.848.44.41.8
Low Dose-0.4-4.213.812.83.43.2

Number of Participants With Change in Investigator Assessment of Tolerability Score: Conjunctival Injection

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Conjunctival Injection. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Hyperpigmentation

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Hyperpigmentation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Irritant/Allergic Contact Dermatitis

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Irritant/Allergic Contact Dermatitis. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Mucosal Toxicity

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Mucosal Toxicity. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Ocular Irritation

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Ocular Irritation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Dryness.

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Dryness. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 2, scale = 0 (none)Day 2, scale = 1 (slight)Day 3, scale = 0 (none)Day 3, scale = 1 (slight)Day 7, scale = 0 (none)Day 28, scale = 0 (none)Day 28, scale = 1 (slight)
High Dose5050505050550
Low Dose4141414141532

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Erythema.

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Erythema. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (0 hours), scale = 2 (moderate)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 1 (6 hours), scale = 2 (moderate)Day 2, scale = 0 (none)Day 2, scale = 1 (slight)Day 3, scale = 0 (none)Day 3, scale = 1 (slight)Day 7, scale = 0 (none)Day 7, scale = 1 (slight)Day 28, scale = 0 (none)
High Dose505005005050505
Low Dose233113114141415

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Peeling

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Peeling. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5050505555
Low Dose3241415555

Number of Participants With Change in Investigator Global Assessment (IGA) Score

"Number of participants with a changed Investigator Global Assessment (IGA) score after single application of NB01; positive number if grade is reduced (e.g. from 3 to 2) or negative number is IGA grade increased.~The Investigator Global Assessment 5-Point Score is a standard FDA acne assessment tool with scoring as follows:~Grade 0-Clear (Clear skin with no inflammatory or non-inflammatory lesions. The category of clear should represent true absence of disease) Grade1-Almost Clear (A few scattered comedones and no more than one small papule) Grade 2-Mild (Some comedones, some papules and pustules; no nodules) Grade 3-Moderate (Many comedones, papules and pustules; one nodule may be present) Grade 4-Severe (Covered with comedones, numerous papules and pustules and no more than a few nodular lesions)" (NCT03450369)
Timeframe: 28 Days

,
InterventionParticipants (Count of Participants)
Participants with changed IGA @ 6 hoursParticipants with changed IGA @ 1 dayParticipants with changed IGA @ 2 daysParticipants with changed IGA @ 6 daysParticipants with changed IGA @ 28 days
High Dose00000
Low Dose00002

Safety Profile and Tolerability of a Singly Applied NB01 Using Acne Lesion Counts.

Absolute Lesion Count: All Lesions for the Whole Face; with higher numbers of lesion representing worsening or more severe acne (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
Interventioncount of lesions (Mean)
ScreeningDay 1 (0 hours)Day 1 (6 hours)Day 2Day 3Day 7Day 28
High Dose38.842.639.838.235.434.232.6
Low Dose49.422.621.031.632.225.625.8

Reviews

3 reviews available for khellin and Chronic Illness

ArticleYear
Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Animals; Chronic Disease; Humans; Inflammation; Keloid; Neoplasms

2019
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
Cellular signaling in tissue regeneration.
    Yonsei medical journal, 2000, Volume: 41, Issue:6

    Topics: Animals; Cell Physiological Phenomena; Chemokines; Chronic Disease; Growth Substances; Humans; Keloi

2000

Trials

2 trials available for khellin and Chronic Illness

ArticleYear
Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids.
    Journal of radiation research, 2014, Volume: 55, Issue:5

    Topics: Adult; Chronic Disease; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Ke

2014
[Bufexamac cream and ointment for the treatment of various dermatoses].
    Dermatologica, 1973, Volume: 146, Issue:1

    Topics: Anti-Inflammatory Agents; Chemical Phenomena; Chemistry; Chronic Disease; Clinical Trials as Topic;

1973

Other Studies

16 other studies available for khellin and Chronic Illness

ArticleYear
The effect of khellin on cardio-pulmonary function in chronic pulmonary disease.
    The Journal of clinical investigation, 1951, Volume: 30, Issue:10

    Topics: Chronic Disease; Heart; Khellin; Lung Diseases

1951
Observations on the clinical use of visammin (khellin).
    Journal of the American Medical Association, 1950, May-13, Volume: 143, Issue:2

    Topics: Angina Pectoris; Chronic Disease; Hypertension, Pulmonary; Khellin; Pulmonary Heart Disease

1950
[Therapy of chronic-obstructive ailments of the respiratory tract].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1970, Jan-06, Volume: 59, Issue:1

    Topics: Bronchitis; Chronic Disease; Humans; Injections, Intravenous; Khellin; Lung Diseases; Lung Diseases,

1970
[Experiences in the treatment of bronchospastic diseases].
    Die Medizinische Welt, 1967, Nov-11, Volume: 45

    Topics: Adult; Aged; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Diphenhydramine; Ephedrine;

1967
Contribution of Autophagy-Notch1-Mediated NLRP3 Inflammasome Activation to Chronic Inflammation and Fibrosis in Keloid Fibroblasts.
    International journal of molecular sciences, 2020, Oct-28, Volume: 21, Issue:21

    Topics: Adolescent; Adult; Aged; Autophagy; Chronic Disease; Female; Fibroblasts; Humans; Inflammasomes; Inf

2020
Keloid formation on the great toe after chronic paronychia secondary to ingrown nail.
    International wound journal, 2013, Volume: 10, Issue:2

    Topics: Chronic Disease; Female; Humans; Keloid; Nails, Ingrown; Paronychia; Secondary Prevention; Wound Hea

2013
Clival keloid after nasopharyngeal radium irradiation masquerading as skull base malignancy.
    The Laryngoscope, 2014, Volume: 124, Issue:8

    Topics: Aged; Bone Diseases; Chronic Disease; Cranial Fossa, Posterior; Diagnosis, Differential; Humans; Kel

2014
Use of a collagen-glycosaminoglycan copolymer (Integra) in combination with adjuvant treatments for reconstruction of severe chest keloids.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents; Chondroitin Sulfates; Chronic Disease; Collagen; Combined Mod

2010
Chronic osteomyelitis in the lower extremity predisposing to the unusual formation of keloids.
    Singapore medical journal, 2011, Volume: 52, Issue:9

    Topics: Ankle; Child; Chronic Disease; Fibula; Humans; Inflammation; Keloid; Lower Extremity; Male; Nigeria;

2011
[Contraindication of operations for keloid scars occurring after BCG administration].
    Khirurgiia, 1981, Issue:6

    Topics: Adolescent; BCG Vaccine; Child; Chronic Disease; Female; Humans; Keloid; Recurrence

1981
Silicone gel sheeting in scar therapy.
    Cutis, 1995, Volume: 56, Issue:1

    Topics: Bandages; Chronic Disease; Cicatrix, Hypertrophic; Dermabrasion; Dermatitis, Irritant; Follow-Up Stu

1995
[Surgical treatment of Verneuil's disease (hidradenitis suppurativa): 15 cases].
    Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:2

    Topics: Abscess; Adult; Chronic Disease; Female; Fistula; Hidradenitis Suppurativa; Humans; Keloid; Male; Mi

2001
Lobomycosis. Report of the eighth Colombian case and review of the literature.
    Journal of cutaneous pathology, 1976, Volume: 3, Issue:4

    Topics: Adult; Blastomycosis; Chronic Disease; Female; Humans; Keloid

1976
[Surgical treatment of elephantiasis of the upper extremities].
    Vestnik khirurgii imeni I. I. Grekova, 1975, Volume: 115, Issue:10

    Topics: Adolescent; Adult; Arm; Child; Child, Preschool; Chronic Disease; Elephantiasis; Female; Humans; Kel

1975
[Effect of cryogenic action on the proteinase activity in patients with keloid and hypertrophic scars].
    Klinicheskaia khirurgiia, 1988, Issue:3

    Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Cicatrix; Cryosurgery; Endopeptidases;

1988
[Treatment of some dermatoses by the intradermal injections of a 10 percent solution of quingamine].
    Sovetskaia meditsina, 1973, Volume: 36, Issue:6

    Topics: Adult; Chloroquine; Chronic Disease; Female; Humans; Injections, Intradermal; Keloid; Lupus Erythema

1973